Analysts forecast that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce $25.23 million in sales for the current quarter, according to Zacks. Seven analysts have issued estimates for Neurocrine Biosciences’ earnings, with estimates ranging from $19.00 million to $31.64 million. The company is scheduled to report its next earnings report after the market closes on Wednesday, November 1st.
On average, analysts expect that Neurocrine Biosciences will report full year sales of $25.23 million for the current financial year, with estimates ranging from $59.20 million to $81.12 million. For the next year, analysts expect that the business will post sales of $166.97 million per share, with estimates ranging from $108.00 million to $203.53 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter last year, the business earned ($0.46) EPS.
A number of equities research analysts have commented on NBIX shares. Cowen and Company restated an “outperform” rating and set a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Piper Jaffray Companies restated a “buy” rating and set a $76.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday. BidaskClub upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Finally, Leerink Swann restated an “outperform” rating and set a $72.00 target price (up from $67.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 10th. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $69.31.
Neurocrine Biosciences (NASDAQ NBIX) traded up 4.70% during mid-day trading on Tuesday, hitting $62.14. 977,979 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $59.49 and a 200 day moving average of $52.30. The stock’s market capitalization is $5.48 billion. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $63.77.
In related news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $1,575,000.00. Following the completion of the transaction, the insider now owns 144,601 shares of the company’s stock, valued at $8,676,060. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the transaction, the insider now directly owns 55,898 shares of the company’s stock, valued at approximately $3,412,013.92. The disclosure for this sale can be found here. Insiders have sold 123,846 shares of company stock valued at $7,004,150 in the last three months. Insiders own 4.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of NBIX. Crossmark Global Holdings Inc. bought a new position in Neurocrine Biosciences in the third quarter valued at about $286,000. Pictet Asset Management Ltd. grew its position in Neurocrine Biosciences by 18.0% in the third quarter. Pictet Asset Management Ltd. now owns 1,345,855 shares of the company’s stock valued at $82,474,000 after acquiring an additional 204,996 shares during the last quarter. First Trust Advisors LP grew its position in Neurocrine Biosciences by 29.0% in the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after acquiring an additional 176,136 shares during the last quarter. Nationwide Fund Advisors grew its position in Neurocrine Biosciences by 3.2% in the third quarter. Nationwide Fund Advisors now owns 124,351 shares of the company’s stock valued at $7,620,000 after acquiring an additional 3,800 shares during the last quarter. Finally, Fisher Asset Management LLC bought a new position in Neurocrine Biosciences in the third quarter valued at about $310,000.
COPYRIGHT VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/25-23-million-in-sales-expected-for-neurocrine-biosciences-inc-nbix-this-quarter.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.